Home LiteratureArticle Details
PMID: 16389312 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Toxin-induced models of Parkinson's disease.

NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics ·Vol. 2 ·No. 3 ·2005-07-00 ·Pages 484-94

Bové J, Prou D, Perier C, Przedborski S

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease that appears essentially as a sporadic condition. It results mainly from the death of dopaminergic neurons in the substantia nigra. PD etiology remains mysterious, whereas its pathogenesis begins to be understood as a multifactorial cascade of deleterious factors. Most insights into PD pathogenesis come from investigations performed in experimental models of PD, especially those produced by neurotoxins. Although a host of natural and synthetic molecules do exert deleterious effects on dopaminergic neurons, only a handful are used in living laboratory animals to recapitulate some of the hallmarks of PD. In this review, we discuss what we believe are the four most popular parkinsonian neurotoxins, namely 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat. The main goal is to provide an updated summary of the main characteristics of each of these four neurotoxins. However, we also try to provide the reader with an idea about the various strengths and the weaknesses of these neurotoxic models.

MeSH Terms
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Animals Dopamine Agents Herbicides Humans Neurotoxins Oxidative Stress/physiology Oxidopamine Paraquat Parkinson Disease, Secondary/chemically induced,pathology Rotenone Sympatholytics
Chemicals
Dopamine Agents Herbicides Neurotoxins Sympatholytics Rotenone Oxidopamine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Paraquat
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bové Jordi
Department of Neurology, Columbia University, New York, New York 10032, USA.
Prou Delphine
Perier Céline
Przedborski Serge
References (122)
122 references, click to expand
  1. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.
    Prog Neurobiol. 2001 Oct;65(2):135-72 PMID: 11403877
  2. Functional coupling of PSST and ND1 subunits in NADH:ubiquinone oxidoreductase established by photoaffinity labeling.
    Biochim Biophys Acta. 2001 Jul 2;1506(1):79-87 PMID: 11418099
  3. Carrier-mediated processes in blood--brain barrier penetration and neural uptake of paraquat.
    Brain Res. 2001 Jul 6;906(1-2):135-42 PMID: 11430870
  4. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.
    Brain Res. 2001 Aug 3;909(1-2):187-93 PMID: 11478935
  5. MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
    J Bioenerg Biomembr. 2004 Aug;36(4):375-9 PMID: 15377875
  6. Variable effects of chronic subcutaneous administration of rotenone on striatal histology.
    J Comp Neurol. 2004 Oct 25;478(4):418-26 PMID: 15384065
  7. A fetal risk factor for Parkinson's disease.
    Dev Neurosci. 2004 Jan-Feb;26(1):11-23 PMID: 15509894
  8. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra.
    Exp Neurol. 1969 Mar;23(3):332-40 PMID: 5767257
  9. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons.
    Eur J Pharmacol. 1968 Dec;5(1):107-10 PMID: 5718510
  10. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.
    Brain Res. 1970 Dec 18;24(3):485-93 PMID: 5494536
  11. Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine.
    Science. 1971 Jun 18;172(3989):1257-8 PMID: 5576164
  12. Rotenone inhibition of spindle microtubule assembly in mammalian cells.
    Exp Cell Res. 1974 Mar 30;85(1):41-6 PMID: 4857086
  13. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system.
    Brain Res. 1976 Feb 6;102(2):201-15 PMID: 1247882
  14. Rotenone inhibition of tubulin self-assembly.
    Biochim Biophys Acta. 1978 Nov 1;543(4):590-4 PMID: 568944
  15. Cerebral damage in paraquat poisoning.
    Histopathology. 1980 Mar;4(2):185-95 PMID: 7358347
  16. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.
    Brain Res. 1980 Aug 11;195(1):123-37 PMID: 6105003
  17. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.
    Psychiatry Res. 1979 Dec;1(3):249-54 PMID: 298352
  18. Chemical neurotoxins as denervation tools in neurobiology.
    Annu Rev Neurosci. 1980;3:169-87 PMID: 6106449
  19. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
    Science. 1983 Feb 25;219(4587):979-80 PMID: 6823561
  20. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
    Can J Neurol Sci. 1984 Feb;11(1 Suppl):160-5 PMID: 6608979
  21. Oxy-radical toxicity in catecholamine neurons.
    Neurotoxicology. 1984 Spring;5(1):77-82 PMID: 6326007
  22. Quantification of lesion-induced dopaminergic supersensitivity using the rotational model in the mouse.
    Brain Res. 1985 Mar 25;330(2):358-63 PMID: 3921193
  23. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey.
    Proc Natl Acad Sci U S A. 1985 Dec;82(24):8780-4 PMID: 3909155
  24. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
    Neurosci Lett. 1985 Dec 18;62(3):389-94 PMID: 3912685
  25. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry.
    Brain Res Bull. 1986 Aug;17(2):225-36 PMID: 3094835
  26. A case of fatal rotenone poisoning in a child.
    J Forensic Sci. 1986 Oct;31(4):1492-8 PMID: 3783116
  27. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
    Ann Neurol. 1986 Oct;20(4):449-55 PMID: 3024555
  28. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.
    J Neurosci. 1987 Sep;7(9):2927-35 PMID: 3114439
  29. MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.
    Environ Health Perspect. 1987 Nov;75:45-51 PMID: 3319563
  30. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems.
    J Neurosci. 1987 Dec;7(12):3915-34 PMID: 2891799
  31. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.
    Neurology. 1997 Jun;48(6):1583-8 PMID: 9191770
  32. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.
    J Neurosci. 1997 Sep 15;17(18):7111-8 PMID: 9278545
  33. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age.
    Cell Transplant. 1997 Nov-Dec;6(6):557-69 PMID: 9440865
  34. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living.
    Neurology. 1998 May;50(5):1346-50 PMID: 9595985
  35. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
    N Engl J Med. 1998 Oct 15;339(16):1105-11 PMID: 9770557
  36. Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model.
    Jpn J Pharmacol. 1998 Sep;78(1):23-9 PMID: 9804058
  37. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.
    Brain Res. 1999 Mar 27;823(1-2):1-10 PMID: 10095006
  38. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid.
    Ann Neurol. 1999 May;45(5):640-51 PMID: 10319887
  39. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure.
    Ann Neurol. 1999 Oct;46(4):598-605 PMID: 10514096
  40. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease.
    Antioxid Redox Signal. 2005 May-Jun;7(5-6):685-93 PMID: 15890013
  41. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set.
    Cereb Cortex. 2001 Nov;11(11):1015-26 PMID: 11590111
  42. Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions.
    Stereotact Funct Neurosurg. 2000;75(2-3):66-75 PMID: 11740172
  43. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.
    J Biol Chem. 2002 Jan 18;277(3):1641-4 PMID: 11707429
  44. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons.
    J Neurosci. 2002 Feb 1;22(3):782-90 PMID: 11826108
  45. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model.
    Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2344-9 PMID: 11782534
  46. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.
    Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4708-13 PMID: 11917105
  47. Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys.
    Nucl Med Biol. 2002 Jul;29(5):561-7 PMID: 12088726
  48. Animal models of neurological deficits: how relevant is the rat?
    Nat Rev Neurosci. 2002 Jul;3(7):574-9 PMID: 12094213
  49. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
    Neurobiol Dis. 2002 Jul;10(2):119-27 PMID: 12127150
  50. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
    Synapse. 2002 Dec 15;46(4):251-7 PMID: 12373740
  51. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
    Exp Neurol. 2004 Jun;187(2):418-29 PMID: 15144868
  52. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.
    Parkinsonism Relat Disord. 2004 Jul;10(5):297-304 PMID: 15196509
  53. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats.
    J Neurochem. 2004 Jul;90(1):29-39 PMID: 15198664
  54. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
    Neurobiol Dis. 2004 Jun;16(1):110-23 PMID: 15207268
  55. Model experiments on the molecular mechanism of action of 6-hydroxydopamine.
    Mol Pharmacol. 1971 Mar;7(2):147-54 PMID: 5125851
  56. Stereotaxic mapping of the monoamine pathways in the rat brain.
    Acta Physiol Scand Suppl. 1971;367:1-48 PMID: 4109331
  57. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system.
    Acta Physiol Scand Suppl. 1971;367:95-122 PMID: 4332694
  58. Enhancement of audiogenic seizure by 6-hydroxydopamine.
    J Pharm Pharmacol. 1972 Nov;24(11):913-4 PMID: 4405660
  59. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.
    Behav Brain Res. 2002 Oct 17;136(1):317-24 PMID: 12385818
  60. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype.
    Neurotoxicology. 2002 Oct;23(4-5):621-33 PMID: 12428734
  61. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
    Exp Neurol. 2003 Jan;179(1):9-16 PMID: 12504863
  62. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats.
    J Neurochem. 2003 Feb;84(3):491-502 PMID: 12558969
  63. Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration.
    J Neurochem. 2003 Apr;85(1):82-6 PMID: 12641729
  64. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity.
    J Neurochem. 2003 May;85(3):651-61 PMID: 12694391
  65. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration.
    J Neurosci. 2003 Apr 15;23(8):3095-9 PMID: 12716914
  66. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.
    J Neurosci. 2003 Apr 15;23(8):3316-24 PMID: 12716939
  67. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Nat Med. 2003 Jun;9(6):762-7 PMID: 12740572
  68. Parkinson's disease: mechanisms and models.
    Neuron. 2003 Sep 11;39(6):889-909 PMID: 12971891
  69. alpha-Synuclein locus triplication causes Parkinson's disease.
    Science. 2003 Oct 31;302(5646):841 PMID: 14593171
  70. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
    Ann Neurol. 2003 Nov;54(5):599-604 PMID: 14595649
  71. Rotenone induces non-specific central nervous system and systemic toxicity.
    FASEB J. 2004 Apr;18(6):717-9 PMID: 14766796
  72. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons.
    J Neurosurg. 2004 Apr;100(4):679-87 PMID: 15070123
  73. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Behav Brain Res. 2004 May 5;151(1-2):117-24 PMID: 15084427
  74. Dopamine depletion impairs precursor cell proliferation in Parkinson disease.
    Nat Neurosci. 2004 Jul;7(7):726-35 PMID: 15195095
  75. Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone.
    Eur J Neurosci. 2004 Jul;20(2):575-9 PMID: 15233767
  76. No evidence for new dopaminergic neurons in the adult mammalian substantia nigra.
    Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10177-82 PMID: 15210991
  77. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway.
    J Biol Chem. 2004 Jul 30;279(31):32626-32 PMID: 15155744
  78. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates.
    Eur J Neurosci. 2004 Sep;20(5):1371-8 PMID: 15341609
  79. The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems.
    J Neurosci. 1987 Dec;7(12):3935-44 PMID: 2891800
  80. Paraquat poisoning by skin absorption: a review.
    Hum Toxicol. 1988 Jan;7(1):15-9 PMID: 3278972
  81. Differential effects of 6-hydroxydopamine on the two types of nerve vesicles and dopamine and noradrenaline content in mesenteric arterial vessels.
    J Auton Pharmacol. 1988 Mar;8(1):1-10 PMID: 3134357
  82. Brain damage due to paraquat poisoning: a fatal case with neuropathological examination of the brain.
    Neurotoxicology. 1988 Summer;9(2):243-8 PMID: 3205434
  83. Dominant effects of tubulin overexpression in Saccharomyces cerevisiae.
    Mol Cell Biol. 1989 Mar;9(3):1049-59 PMID: 2657385
  84. Cognitive change following MPTP exposure.
    Neurology. 1990 Feb;40(2):261-4 PMID: 2300245
  85. MPTP-induced parkinsonism.
    Prog Neurobiol. 1990;34(2):107-14 PMID: 2181530
  86. Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubulin and beta-tubulin.
    Mol Cell Biol. 1990 Oct;10(10):5295-304 PMID: 2204812
  87. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
    Science. 1990 Sep 21;249(4975):1436-8 PMID: 2402638
  88. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
    Science. 1990 Dec 7;250(4986):1429-32 PMID: 2147780
  89. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
    Neurology. 1991 Feb;41(2 ( Pt 1)):202-5 PMID: 1992362
  90. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP.
    Brain Res. 1990 Sep 10;527(1):7-20 PMID: 1980841
  91. Transplantation of microencapsulated bovine chromaffin cells reduces lesion-induced rotational asymmetry in rats.
    Brain Res. 1991 Sep 27;560(1-2):43-9 PMID: 1760745
  92. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Proc Natl Acad Sci U S A. 1992 May 1;89(9):3859-63 PMID: 1570304
  93. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations.
    Adv Neurol. 1993;60:600-8 PMID: 8380528
  94. Transplantation of fetal nigral cells reverses the increase of preproenkephalin mRNA levels in the rat striatum caused by 6-OHDA lesion of the dopaminergic nigrostriatal pathway: a quantitative in situ hybridization study.
    Brain Res Mol Brain Res. 1993 May;18(3):221-7 PMID: 8497184
  95. Environmental antecedents of young-onset Parkinson's disease.
    Neurology. 1993 Jun;43(6):1150-8 PMID: 8170560
  96. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats.
    Brain Res. 1993 Jun 11;613(2):347-51 PMID: 8186990
  97. 6-Hydroxydopamine lesions reduce BDNF mRNA levels in adult rat brain substantia nigra.
    Neuroreport. 1994 Jan 12;5(4):429-32 PMID: 8003668
  98. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.
    Neuroscience. 1994 Mar;59(2):401-15 PMID: 7516500
  99. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
    Exp Neurol. 1994 Apr;126(2):195-204 PMID: 7925820
  100. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.
    Ann Neurol. 1994 Nov;36(5):765-70 PMID: 7979223
  101. Canine myocardial beta-adrenergic, muscarinic receptor densities after denervation: a PET study.
    J Nucl Med. 1995 Jan;36(1):140-6 PMID: 7799068
  102. Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model.
    Brain Res. 1994 Oct 17;660(2):255-60 PMID: 7820694
  103. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
    Brain Res. 1994 Oct 31;662(1-2):69-74 PMID: 7859092
  104. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
    J Neurosci. 1995 May;15(5 Pt 2):3863-75 PMID: 7751951
  105. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation.
    J Neurosci. 1995 Sep;15(9):5912-8 PMID: 7666176
  106. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
    Neuroscience. 1995 Aug;67(3):631-47 PMID: 7675192
  107. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death.
    Neurodegeneration. 1995 Jun;4(2):131-7 PMID: 7583676
  108. Effects of unilateral 6-hydroxydopamine lesions on neuropeptide immunoreactivity in the basal ganglia of the common marmoset, Callithrix jacchus, a quantitative immunohistochemical analysis.
    J Chem Neuroanat. 1995 Oct;9(3):155-64 PMID: 8588831
  109. Functional recovery in parkinsonian monkeys treated with GDNF.
    Nature. 1996 Mar 21;380(6571):252-5 PMID: 8637574
  110. Chemical cardiac sympathetic denervation hampers defibrillation in the dog.
    J Cardiovasc Electrophysiol. 1997 Jan;8(1):62-7 PMID: 9116969
  111. Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra.
    J Neurosci. 1997 Mar 15;17(6):2030-9 PMID: 9045731
  112. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra.
    Brain Res. 1997 Apr 4;753(1):157-62 PMID: 9125443
  113. A mechanism of paraquat toxicity involving nitric oxide synthase.
    Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12760-5 PMID: 10535996
  114. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.
    J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):313-6 PMID: 10675212
  115. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?
    Brain Res. 2000 Aug 11;873(2):225-34 PMID: 10930548
  116. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
    Science. 2000 Oct 27;290(5492):767-73 PMID: 11052933
  117. In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone.
    J Neurochem. 2000 Dec;75(6):2611-21 PMID: 11080215
  118. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
    Nat Neurosci. 2000 Dec;3(12):1301-6 PMID: 11100151
  119. Increased striatal dopamine turnover following acute administration of rotenone to mice.
    Brain Res. 2000 Dec 8;885(2):283-8 PMID: 11102582
  120. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.
    J Neurosci. 2000 Dec 15;20(24):9207-14 PMID: 11124998
  121. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety.
    J Neurochem. 2001 Mar;76(5):1265-74 PMID: 11238711
  122. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease.
    Behav Brain Res. 2001 Jul;122(1):79-92 PMID: 11287079
Article Info
Journal
NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics
Abbr.
NeuroRx
ISSN
1545-5343
DOI
10.1602/neurorx.2.3.484
Published
2005-07-00
Pages
484-94
Language
English
Region
United States
NLM ID
101189456
PMCID
PMC1144492
Subset
IM
Grants
NINDS NIH HHS · R01 NS38586 · United States
NINDS NIH HHS · P50 NS038370 · United States
NINDS NIH HHS · P50 NS38370 · United States
NINDS NIH HHS · P01 NS11766-27A2 · United States
NINDS NIH HHS · P01 NS011766 · United States
NINDS NIH HHS · R01 NS042269 · United States
NINDS NIH HHS · R01 NS038586 · United States
NINDS NIH HHS · NS42269 · United States
External Links
PubMed source DOI: 10.1602/neurorx.2.3.484 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2